Literature DB >> 7670280

Evaluation of hormonal testing in the screening for in vitro fertilization (IVF) of women with tubal factor infertility.

M R Laufer1, A E Floor, K E Parsons, K M Kuntz, R L Barbieri, A J Friedman.   

Abstract

PURPOSE: To evaluate the frequency of abnormal prolactin and thyroid stimulating hormone (TSH) test results in ovulatory women with tubal factor infertility who were screened for in vitro fertilization (IVF).
METHODS: Charts were identified from 112 ovulatory women with follicle stimulating hormone (FSH) < 20 mIU/ml who were diagnosed with tubal factor infertility and were screened for IVF with thyroid stimulating hormone (TSH) and prolactin levels. Women previously diagnosed with thyroid disease were subsequently excluded and 98 subjects remained. All subjects were determined to be ovulatory by biphasic basal body temperature (BBT) charts, luteal phase progesterone > 4 ng/ml, or endometrial biopsy revealing secretory endometrium. Results of cycle day 3 serum TSH and prolactin concentrations were recorded. The normal range for each test reflects the geometric mean +/- 2 standard deviations (i.e., 95% interval), as obtained from the reference laboratory. Under this construct, hypothesis tests were performed to determine whether or not our study population was consistent with the reference range of normal hormone levels. Under the null hypothesis (normal levels), we expected 5% of the TSH tests to be abnormal (i.e., high or low levels), and 2.5% of the prolactin tests to be abnormal (i.e., high levels). Exact bionomial confidence intervals and P-values were calculated. We also tested for age trend in the proportion of abnormal results.
RESULTS: Study subjects had an age range of 25-43. In the study group, 4 (0.041) out of the 98 women screened had abnormal TSH levels. Of these four abnormal TSH results, three were elevated (i.e., TSH > 4.6 microIU/ml) and one was low (i.e., TSH < 0.6 microIU/ml). The frequency of an abnormal TSH value was not significantly different from that expected from the reference laboratory normal values (95% CI 0.011, 0.101). Of the 98 subjects, 7 (0.071) had abnormal prolactin levels, which was significantly different from that expected from the reference laboratory normal values (95% CI 0.029, 0.142; P = 0.023). When stratified by age, there was no observed trend of abnormalities for TSH or prolactin levels with increasing age.
CONCLUSIONS: In ovulatory women presenting for IVF with tubal factor infertility, our results show that routine screening with a TSH test does not yield a significantly higher proportion of abnormal results than that expected from the reference laboratory normal values. However, prolactin level screening was found to yield a higher incidence of abnormal tests than expected from the reference laboratory normal values.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670280     DOI: 10.1007/bf02211376

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  3 in total

Review 1.  Screening for thyroid disease.

Authors:  M Helfand; L M Crapo
Journal:  Ann Intern Med       Date:  1990-06-01       Impact factor: 25.391

2.  Routine thyroid function tests in infertile women: are they necessary?

Authors:  E Shalev; S Eliyahu; M Ziv; M Ben-Ami
Journal:  Am J Obstet Gynecol       Date:  1994-11       Impact factor: 8.661

3.  Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism.

Authors:  E C Ridgway; D S Cooper; H Walker; D Rodbard; F Maloof
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

  3 in total
  1 in total

1.  Serum prolactin and TSH in an in vitro fertilization population: is there a link between fertilization and thyroid function?

Authors:  D W Cramer; P M Sluss; R D Powers; P McShane; E S Ginsburgs; M D Hornstein; A F Vitonis; R L Barbieri
Journal:  J Assist Reprod Genet       Date:  2003-06       Impact factor: 3.412

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.